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Summary
Background The updated American Joint Committee on Cancer (AJCC) staging cri-
teria for melanoma remain unable to identify high-risk stage I tumour subsets.
Objectives To determine the utility of epidermal autophagy and beclin 1 regulator
1 (AMBRA1)/loricrin (AMLo) expression as a prognostic biomarker for AJCC
stage I cutaneous melanoma.
Methods Peritumoral AMBRA1 expression was evaluated in a retrospective discov-
ery cohort of 76 AJCC stage I melanomas. AMLo expression was correlated with
clinical outcomes up to 12 years in two independent powered, retrospective vali-
dation and qualification cohorts comprising 379 AJCC stage I melanomas.
Results Decreased AMBRA1 expression in the epidermis overlying primary melano-
mas in a discovery cohort of 76 AJCC stage I tumours was associated with a 7-
year disease-free survival (DFS) rate of 815% vs. 100% survival with maintained
AMBRA1 (P < 0081). Following an immunohistochemistry protocol for semi-
quantitative analysis of AMLo, analysis was undertaken in validation (n = 218)
and qualification cohorts (n = 161) of AJCC stage I melanomas. Combined cohort
analysis revealed a DFS rate of 983% in the AMLo low-risk group (n = 239) vs.
854% in the AMLo high-risk cohort (n = 140; P < 0001). Subcohort multivari-
ate analysis revealed that an AMLo hazard ratio (HR) of 404 [95% confidence
interval (CI) 169–966; P = 0002] is a stronger predictor of DFS than Breslow
depth (HR 297, 95% CI 093–956; P = 0068) in stage IB patients.
Conclusions Loss of AMLo expression in the epidermis overlying primary AJCC
stage I melanomas identifies high-risk tumour subsets independently of Breslow
depth.
What’s already known about this topic?
• There is an unmet clinical need for biomarkers of early-stage melanoma.
• Autophagy and beclin 1 regulator 1 (AMBRA1) is a proautophagy regulatory pro-
tein with known roles in cell proliferation and differentiation, and is a known
tumour suppressor.
• Loricrin is a marker of epidermal terminal differentiation.
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What does this study add?
• AMBRA1 has a functional role in keratinocyte/epidermal proliferation and differen-
tiation.
• The combined decrease/loss of peritumoral AMBRA1 and loricrin is associated with
a significantly increased risk of metastatic spread in American Joint Committee on
Cancer (AJCC) stage I tumours vs. melanomas, in which peritumoral AMBRA1 and
loricrin are maintained, independently of Breslow depth.
What is the translational message?
• The integration of peritumoral epidermal AMBRA1/loricrin biomarker expression
into melanoma care guidelines will facilitate more accurate, personalized risk strati-
fication for patients with AJCC stage I melanomas, thereby facilitating stratification
for appropriate follow-up and informing postdiagnostic investigations, including
sentinel lymph node biopsy, ultimately resulting in improved disease outcomes
and rationalization of healthcare costs.
Melanoma is one of the most devastating skin cancers, with a
worldwide incidence that continues to rise.1,2 Although the
introduction of targeted and immune therapies has revolution-
ized treatment of metastatic disease, the largest proportion of
patients presenting to clinicians have thin, early-stage melano-
mas yet to benefit from therapeutic innovation, in part related
to a lack of credible biomarkers of disease progression.
Currently, disease staging and risk prediction is based on
histological characterization of the primary tumour, including
depth of tumour invasion (Breslow depth) and the presence
of epidermal ulceration, forming the basis of the seventh edi-
tion of the American Joint Committee on Cancer (AJCC) stag-
ing criteria.3 The recently updated eighth edition of the AJCC
guidelines came into effect in January 2018,4 with removal of
mitotic count and reduction of Breslow depth for stage IA
melanomas to 08 mm. However, these criteria are still unable
to identify reliably which individuals with seemingly low-risk,
early melanomas are at specific risk of disease progression,
occurring in up to 15% of patients with AJCC stage I mela-
noma.4,5 An urgent unmet need for credible prognostic
biomarkers able to identify patients with high-risk, early-stage
melanomas, facilitating appropriate counselling and follow-up
[including guidance on the need for sentinel lymph node
biopsy (SLNB)] or access to clinical trials and potentially adju-
vant systemic treatment,6,7 thus remains.
We have identified two protein markers, autophagy and
beclin 1 regulator 1 (AMBRA1) and loricrin, in the epidermis
overlying primary melanomas, whose expression is lost in
high-risk AJCC stage I melanomas, but which are retained over
genuinely low-risk tumours. The role of AMBRA1 (a proau-
tophagy regulatory protein) in melanoma progression was ini-
tially evaluated by immunohistochemistry (IHC) in a
retrospective melanoma discovery cohort following previous
reports of the role of autophagy in melanomagenesis;8,9
however, unlike previously investigated autophagy biomarkers
such as p62,8 AMBRA1 revealed variations in expression
within the epidermis overlying primary melanomas, rather
than within the tumour itself, suggesting a specific role for
this protein in epidermal differentiation.9 To investigate peri-
tumoral AMBRA1 as a potential prognostic marker, we initially
evaluated immunohistochemical semi-quantitative expression
in a retrospective discovery cohort of AJCC stage I melanomas.
However, although loss of peritumoral AMBRA1 expression
correlated with disease progression with an assay sensitivity of
100%, the relatively low assay specificity (33%) hindered its
clinical utility. Subsequently, to improve specificity, peritu-
moral epidermal AMBRA1 expression was assessed in combi-
nation with epidermal loricrin (as a marker of keratinocyte
terminal differentiation), with the primary aim of this study
to validate combined peritumoral AMBRA1 and loricrin
(AMLo) expression as a prognostic biomarker for early-stage
melanoma.
Materials and methods
Study design
Patient cohort selection
This study included three independent, statistically powered
retrospective cohorts of AJCC stage I melanomas defined by
the AJCC Cancer Staging Manual, seventh edition (Fig. 1). All
cohorts were accessed following research ethics committee
permission (ref. 08/H0906/95+5_Lovat). All steps of biomar-
ker development followed the Cancer Research UK Prognostic
Biomarkers Roadmap and were reported in line with the
REMARK (REporting recommendations for tumour MARKer
prognostic studies) guidelines.10,11 The initial discovery cohort
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of 76 patients was derived from Newcastle Hospitals National
Health Service Foundation Trust (NUTH), with subsequent
discovery stage 2 (validation) and qualification retrospective
cohorts derived from James Cook University Hospital (JCUH;
n = 218) and University Hospital of North Durham, respec-
tively (UHND; n = 161). Full patient selection and cohort
demographics are described in Figure S1 (see Supporting
Information).
Semi-quantitative immunohistochemistry analysis of
autophagy and beclin 1 regulator 1 and loricrin
Formalin-fixed, paraffin-embedded tissue sections (5 lm)
were derived from primary melanomas from each cohort. The
IHC methodology for AMBRA1 (Abcam, Cambridge, U.K.),
loricrin (Abcam) and cytokeratin 5 (Novocastra; Leica Biosys-
tems, Milton Keynes, U.K.) are detailed in Appendix S1 (see
Supporting Information).
Semi-quantitative analysis of epidermal AMBRA1 expression
was undertaken using Leica Digital Image Hub software (Leica
Biosystems). Up to 10 representative 9200 microscope fields
were analysed for mean positive pixel intensity of AMBRA1
expression levels and compared to the mean AMBRA1 expres-
sion in the epidermis directly above the melanoma, allowing a
relative percentage expression change to be calculated with the
normal epidermis considered as 100% expression.
Validation of autophagy and beclin 1 regulator 1 and
loricrin scoring
Visual AMBRA1 and loricrin scoring for all cohorts was under-
taken by three individuals blinded to outcomes (R.E., E.C.,
G.W.); consensus agreement was reached for all samples. The
‘by-eye’ analysis was grouped as either ‘maintained AMBRA1’ or
‘decreased/lost AMBRA1’. ‘Maintained AMBRA1’ was defined as
no discernible difference in AMBRA1 expression between normal
and peritumoral epidermis. ‘Decrease/lost AMBRA1’ was defined
as any decrease or complete loss of AMBRA1 expression between
normal and peritumoral epidermis.
All loricrin expression analysis was undertaken by eye, and
loss of expression defined as any discernible break in the con-
tinuity of expression in the stratum corneum (Fig. S2; see
Supporting Information).
Statistical analysis
Survival analyses were conducted using the R function
coxph(). Univariate estimates presented are coefficients, with
95% confidence intervals (CIs), resulting from a Cox fit with
only that covariate as a predictor, while multivariate estimates
are the associated coefficient from a full additive model,
including all reported covariates (in particular, we did not refit
to exclude nonsignificant predictors and considered no inter-
action terms).
Survival curves were generated using the R function
survfit() to present Kaplan–Meier curves for a univariate
model based on AMLo status, with presented P-values as the
result of a log-rank (score) test for the associated univariate
Cox model.
Statistical analysis for disease-free survival (DFS) was
planned for each cohort independently, as well as in combina-
tion for the JCUH and UHND cohorts. Further subcohort anal-
ysis was undertaken in AJCC stage IA and IB patients, as well
as patients eligible for SLNB under the current UK National
Institute for Health and Care Excellence guidelines (i.e. with a
Breslow depth > 1 mm).
For the analysis of SLNB datasets, post-test odds were used
to calculate the positive and negative predictive values (i.e.
clinically relevant measures of diagnostic accuracy). These are
calculated by multiplying the pretest probability of a positive
(negative) result (the prevalence or 1 – prevalence) with the
diagnostic likelihood ratio of a positive (negative) test.12
Results
Peritumoral autophagy and beclin 1 regulator 1
expression and disease-free survival in the Newcastle
Hospitals National Health Service Foundation Trust
discovery cohort
To identify an association between epidermal AMBRA1 expres-
sion overlying primary tumours (peritumoral AMBRA1) and
DFS in patients with AJCC stage I melanoma, 76 patients
within the NUTH cohort were stratified as either having main-
tained or decreased AMBRA1 expression by visual analysis of
peritumoral AMBRA1 expression (Fig. 2). All samples were
also analysed for cytokeratin 5 (Fig. 2a), a pan-epidermal
marker, which revealed no association between the degree of
melanoma epidermal invasion and peritumoral AMBRA1
expression.
Kaplan–Meier survival analysis revealed reduced 7-year DFS
in patients with decreased peritumoral epidermal AMBRA1
expression vs. 22 patients with maintained AMBRA1 expres-
sion [815% vs. 100% (P = 0081); Fig. 2b]. However, the
hazard ratio (HR) for disease recurrence among patients with
decreased AMBRA1 expression vs. maintained expression could
not be assessed owing to a lack of events in the maintained
cohort.
Although decreased AMBRA1 expression was associated
with a reduced 7-year DFS with a sensitivity for identifying
patients at risk of disease progression of 100%, the specificity
of the test was only 333%, limiting clinical utility.
Autophagy and beclin 1 regulator 1 as a marker of
epidermal differentiation
To further underpin the role of AMBRA1 in epidermal differ-
entiation, Western blot analysis for the expression of AMBRA1
and associated epidermal proteins was performed in primary
keratinocytes undergoing calcium-induced differentiation
in vitro. Results revealed a consistent time-dependent increase
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Fig 1. Study design followed the Cancer Research UK prognostic biomarker roadmap.10 Following initial identification of varied autophagy and
beclin 1 regulator 1 (AMBRA1) epidermal expression in formalin-fixed, paraffin-embedded American Joint Committee on Cancer (AJCC; 2009)
stage I and II primary cutaneous melanoma, an immunohistochemistry (IHC) assay was developed for initial assessment in a retrospective cohort
of 76 patients with AJCC stage I melanoma derived from the Newcastle Hospital National Health Service Foundation Trust. Following validation
and conversion of the assay to a fully automated IHC system, and the addition of loricrin, two further retrospective cohorts of 218 and 161
patients, respectively, with AJCC (2009) stage I melanomas were analysed for AMBRA1/loricrin expression levels and associated disease-free
survival data. SOP, standard operating procedure.
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in AMBRA1 expression in line with increased differentiation;
highlighted by decreased expression of cytokeratin 14 (a mar-
ker of basal keratinocytes) and increased loricrin expression.
Conversely, small interfering RNA-mediated knockdown of
AMBRA1 in primary keratinocytes resulted in deregulated dif-
ferentiation, as evidenced by downregulation of loricrin at
both the mRNA and protein level (Fig. S3; see Supporting
Information).
Combined autophagy and beclin 1 regulator 1/loricrin
peritumoral epidermal expression and disease-free
survival in the James Cook University Hospital and
University Hospital of North Durham validation cohorts
To compare the method of determining AMBRA1 expression,
both visual and semi-quantitative analysis of peritumoral
AMBRA1 expression were performed in the JCUH cohort
(Fig. 3 and Fig. S4; see Supporting Information). The results
revealed a significant difference in median percentage loss of
AMBRA1 expression from 112% in the ‘no visual loss’
group to 841% in the ‘visual loss present’ group (Fig. 3b;
Mann–Whitney, P <0001). As such, any decrease or loss of
peritumoral epidermal AMBRA1 expression when compared
‘by eye’ with the expression of AMBRA1 in normal epider-
mis was deemed as ‘high risk’ (Fig. S4). Furthermore, these
observations confirmed the robustness of visual analysis,
which was subsequently used alone for all other cohort anal-
yses, and highlighted the major benefit of having an internal
control (normal epidermis) present in each primary tumour
excision sample.
Visual assessment of loricrin also defined two distinct sub-
sets (Fig. 3b and Fig. S5; see Supporting Information).
(a)
(b)
Fig 2. Relationship between peritumoral autophagy and beclin 1 regulator 1 (AMBRA1) expression and disease-free survival in the Newcastle
discovery American Joint Committee on Cancer (AJCC) stage I melanoma cohort. (a) Representative photomicrographs of immunohistochemical
AMBRA1 (pink) or cytokeratin 5 (CK5; brown) staining in normal or matched peritumoral epidermis, where (e) represents the epidermis and
(m) identifies melanoma (Breslow depth 12 mm, scale bars 100 lm). (b) AMBRA1 levels in the peritumoral epidermis of AJCC stage I
melanomas were determined by visual inspection by a pathologist and defined as maintained or decreased. Estimated 7-year disease-free survival
rates were determined with the Kaplan–Meier method and compared by a two-sided log-rank test (815% vs. 100%; P < 0081).
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To confirm the association of decreased DFS with alterations
of the peritumoral epidermis, IHC expression of loricrin was
also assessed in a small subgroup of the NUTH discovery
cohort of AJCC stage I melanomas, revealing an association
between peritumoral loricrin loss and decreased DFS with a
high degree of assay specificity but lower sensitivity (Fig. 4).
However, strikingly, when epidermal loricrin expression was
combined with epidermal AMBRA1 expression, the results
revealed that decreased peritumoral expression of both mark-
ers was associated with 100% sensitivity and specificity for
identifying truly high-risk melanomas in this subcohort
(Fig. S6; see Supporting Information).
Consequently, the combination of AMLo was deemed as
‘high risk’ if AMBRA1 peritumoral expression was decreased
or lost, and if there was any apparent break in the continuous
expression of epidermal loricrin.
Subsequent analysis of combined epidermal AMLo expression
was undertaken in two further validation cohorts of AJCC stage
I melanoma patients (JCUH and UHND cohorts). These cohorts
were statistically powered to provide 80% and ~95% power,
respectively, to detect an HR of > 40 (as per biomarker discov-
ery cohort) at the P = 005 level, assuming equal group sizes
and a representative number of metastatic events as expected in
AJCC stage I melanomas (~10%).3 A detailed description of
patient datasets for these analyses is provided in Figure S3 (see
Supporting Information).
The IHC protocol was further refined from the discovery
cohort as detailed in Appendix S1 (see Supporting Informa-
tion), and undertaken on a fully automated clinical platform
within the JCUH Pathology Department (Fig. 3b).
Analysis of 10-year DFS in the JCUH cohort of 218 AJCC
stage I melanomas revealed reduced DFS in 60 patients stratified
as AMLo high-risk vs. 158 patients defined as AMLo low-risk
[833% vs. 987% (P = 0001); Fig. 5a] with a multivariate HR
for disease recurrence in patients with high-risk AMLo expres-
sion of 728 [95% CI 236–2241 (P < 0001); Fig. 5b].
Analysis of DFS over 12 years in the 161 patients in the
UHND cohort also demonstrated reduced DFS in 80 patients
with high-risk AMLo expression vs. 81 patients with low-risk
AMLo expression [888% vs. 975% (P = 003); Fig. 5c]. The
multivariate HR for disease recurrence in patients with high-
risk AMLo expression in this cohort was 258 [95% CI 087–
765 (P = 0088); Fig. 5d].
By combining the two validation cohorts to increase the
power to detect an effect of AMLo alone (Fig. 6), the results
revealed a highly significant reduction in DFS in 140 patients
with high-risk AMLo expression compared with 239 patients
with low-risk AMLo expression [855% vs. 983%;
(P < 0001); Fig. 6a]. The multivariate HR for disease recur-
rence among patients with high-risk AMLo expression was
389 [95% CI 18–841 (P < 0001); Fig. 6b]. As a further
guide to clinical utility, analysis of the combined cohort
(a) (b)
Fig 4. Relationship between peritumoral autophagy and beclin 1 regulator 1 (AMBRA1)/loricrin expression and disease-free survival in sentinel
lymph node biopsy (SLNB)-eligible patients. (a) Post-test probabilities after SLNB for metastatic melanoma in MSLT-1 (Multicenter Selective
Lymphadenectomy Trial) intermediate-thickness cohort. (b) Post-test probabilities after analysis of AMBRA1/loricrin expression in SLNB-eligible
American Joint Committee on Cancer stage I melanoma samples.
Fig 3. Immunohistochemistry analysis of autophagy and beclin 1 regulator 1 (AMBRA1) protein expression in the James Cook University Hospital
American Joint Committee on Cancer stage I cohort. (a) Semi-quantitative scoring of AMBRA1 (percentage decrease in peritumoral epidermis vs.
normal epidermis at the section margins) vs. visual scoring of either maintained or decreased peritumoral AMBRA1 [horizontal bar indicates
median with interquartile range (median 112% vs. 841%; Mann–Whitney, P < 0001)]. (b) Representative photomicrographs of maintained
(low risk) or decreased (high risk) immunohistochemical AMBRA1 staining in peritumoral epidermis at 9100 and 9200 magnification (scale bars
100 lm). (c) Representative photomicrographs of continuous (low risk) or broken (high risk) immunohistochemical loricrin staining in
peritumoral epidermis at 9100 and 9200 magnification (scale bars 100 lm). ****indicates value is P < 0.00001.
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revealed a sensitivity of 826%, specificity of 66%, a positive
predictive value of 136% and, most importantly, a negative
predictive value of 983% (Fig. 6b).
Furthermore, subgroup analysis of the study combined
cohort of stage IB (eighth edition AJCC) patient set (Fig. 6c)
revealed a statistically stronger correlation between AMLo
stratification and DFS. In this subcohort, DFS was 971% in
the AMLo low-risk group (n = 105) vs. only 796% in the
AMLo high-risk cohort [n = 97 (P < 0001); Fig. 6c]. Multi-
variate analysis revealed an AMLo HR of 404 [95% CI 169–
966 (P = 0002); Fig. 6d], whereas there was less of a corre-
lation between Breslow depth and overall DFS [multivariate
analysis HR 297, 95% CI 093–956 (P = 0068); Fig. 6d],
suggesting that AMLo is a prognostic marker, independent of
Breslow depth, which is able to stratify patient risk over and
above AJCC staging alone.
Discussion
We are currently experiencing what has been described as the
‘golden age’ of melanoma therapy,13 with an ever-expanding
arsenal of systemic medications available for patients with
metastatic disease, resulting in increased survival periods
beyond the expectations of the most optimistic of clinicians
even 10 years ago.14,15 The thrust of trials is now aimed at
adjuvant initiation of these therapies, which has resulted in
unprecedented results in patients with surgically resected,
AJCC stage III melanomas at high risk of recurrence.16,17 The
natural progression to tackling melanoma finally is the initia-
tion of systemic therapy at the earliest possible point at which
high-risk individuals can be identified, thus stopping the
development of life-threatening metastases or treating them
before they have affected the patient’s health.
As such, a yet-unrealized dream for the management of
melanoma is the ability to identify patients at the highest risk
of progression as close to the time of diagnosis of a primary
melanoma as possible, allowing increased surveillance and ear-
lier therapeutic intervention. Conversely, patients at truly low
risk of disease could be more confidently reassured and fol-
low-up regimes altered. The largest population of patients
affected by melanoma have AJCC stage I disease. As such, any
improvements in the care of this group of patients will affect
the largest number of patients overall, with the associated
potential economic benefits.
(a) (b)
(c) (d)
Fig 5. Relationship between peritumoral autophagy and beclin 1 regulator 1 (AMBRA1)/loricrin expression and disease-free survival in the
validation cohorts. AMBRA1 and loricrin levels in the peritumoral epidermis of American Joint Committee on Cancer stage I melanomas were
determined by visual inspection by a pathologist and defined as maintained or decreased. Ten-year disease-free survival rates were determined
with the Kaplan–Meier method and compared by a two-sided log-rank test in both the (a) James Cook University Hospital [JCUH; 848% vs.
981% (P < 0001)] and (c) University Hospital of North Durham [UHND; 888% vs 975% (P = 0033)] cohorts. Assay performance and
univariate and multivariate cox regression analysis of disease-free survival in the (b) JCUH and (d) UHND cohorts. CI, confidence interval.
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AJCC staging of melanoma alone, relying on Breslow depth
and the presence of ulceration, is not a perfect predictor of
outcome in the lowest-risk, stage I group, where a small but
significant proportion of patients will still die of their disease.
Recent evidence-based changes to the AJCC eighth edition
staging criteria highlight a ‘breakpoint’ of 08 mm Breslow
depth, with nonulcerated primaries below this depth classified
as stage IA, with ulcerated tumours < 08 mm, or nonulcer-
ated tumours from 08 to 2 mm Breslow depth, classified as
stage IB. This has increased the number of patients now classi-
fied as having stage IB disease, with implications for increased
surveillance of stage IB patients (5 years of follow-up) vs.
those with stage IA melanoma (1 year of follow-up).
Herein we describe the discovery and validation of the
combined expression of two protein biomarkers, AMBRA1
and loricrin, in the epidermis overlying primary AJCC stage I
melanomas as a highly sensitive and specific prognostic bio-
marker. AMBRA1 is a proautophagy regulatory protein and
our in vitro data further define a functional role for AMBRA1 in
epidermal proliferation, and, like loricrin, in epidermal differ-
entiation.
There is ongoing controversy about the clinical role of
SLNB, with large-scale trials raising questions about the prog-
nostic and therapeutic role of SLNB, as well as highlighting
the associated morbidity and healthcare costs of patients
undergoing the procedure unnecessarily. As with melanoma in
general, improved stratification of those patients at the highest
risk of disease progression would potentially allow SLNB to
further refine individual disease risk.
The Multicenter Selective Lymphadenectomy Trial (MSLT-1)
SLNB trial contained a cohort of 765 intermediate-thickness
primary tumours undergoing SLNB that ranged in Breslow
depth from 1 to 35 mm.18 Overall, the pretest probability of
a patient in this cohort developing a metastasis was 16%. In
patients with a positive SLNB the number developing metas-
tases was higher, giving a post-test probability of developing
metastases in this group of 33% (95% CI 29–36); however, a
negative SLNB was still associated with a 13% chance of
(a)
(c)
(b)
(d)
Fig 6. Relationship between peritumoral autophagy and beclin 1 regulator 1 (AMBRA1)/loricrin expression and disease-free survival in the
combined validation cohorts. AMBRA1 and loricrin levels in the peritumoral epidermis of American Joint Committee on Cancer (AJCC) stage I
melanomas were determined by visual inspection by a pathologist and defined as maintained or decreased. Twelve-year disease-free survival (DFS)
rates were determined with the Kaplan–Meier method and compared by a two-sided log-rank test in the combined validation cohort (861% vs.
979%; P < 0001). (b) Assay performance and univariate and multivariate Cox regression analysis of DFS in the combined cohort. (c) Twelve-
year DFS rates were determined with the Kaplan–Meier method and compared by a two-sided log-rank test in AJCC stage IB melanomas of the
combined validation cohort (805% vs. 962%; P < 0001). (d) Assay performance and univariate and multivariate Cox regression analysis of DFS
in AJCC stage IB melanomas of the combined cohort. CI, confidence interval.
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disease progression (95% CI 11–15%) (Fig. 4).18 Therefore,
these data suggest that a positive SLNB is able to further risk-
stratify patients, yet a negative SLNB adds little to reassure
patients about their true risk of metastasis.
Although analysis has been undertaken in separate cohorts,
assessment of the outcomes in our SLNB-eligible combined
cohort (patients with a Breslow depth > 1 mm, as per U.K.
guidelines) nevertheless revealed that a pretest probability of
metastasis of 10% is increased to 18% (95% CI 12–24) in the
AMLo high-risk group. In contrast, low-risk AMLo was associ-
ated with a post-test probability of only a 14% chance of
metastasis (95% CI 0–5; Fig. 4). In this context, these results
highlight the potential of AMLo as a valuable pre-SLNB test;
identifying those patients that would receive no further benefit
from SLNB, and increasing the positive predictive value of
SLNB through use in only a high-risk, AMLo refined cohort.
In summary, our study reveals AMLo as a novel prognostic
biomarker for early-stage cutaneous melanoma, over and
above AJCC staging alone. This simple, IHC-based marker will
integrate seamlessly into standard clinical pathways of mela-
noma diagnostics, and allow the treating clinician a greater
degree of certainty around disease outcomes. Given the cur-
rent prevailing view that SLNB is a purely prognostic tool, and
considering the cost and morbidity associated with SLNB,
there is potential that the AMLo biomarker may later replace
SLNB. Not only will this benefit the individual patient in terms
of reduced psychological burden from greater clarity of dis-
ease risk, but it will also allow better healthcare resource uti-
lization internationally. As the golden age of melanoma care
continues, the adoption of the AMLo biomarker into clinical
guidelines thus presents a major paradigm shift in melanoma
prognostication and stratified personalized management for
the future.
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